TCTR20211228003已完成4 期
Immunogenicity and safety of ChAdOx1 vaccine (Covid-19 vaccine) in Thai people with underlying disease
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 385
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •1. age more than 18 years old
- •2. Anti-SAR-CoV-2 negative
- •3. diabetes mellitus or
- •4. cirrhosis or
- •5. solid cancer or
- •6. hematologic malignancy or
- •7. chronic kidney disease (GFR <60 ml/mi/1.73 m2)
- •8. rheumatological disease or
- •9. cardiovascular disease
排除标准
- •1. previous covid-19 vaccination
- •2. prior other vaccine in 14 days
- •3. pregnancy
- •4. lactation
研究者
相似试验
招募中
不适用
Comparison of the Immunogenicity of ChAdOx1 nCoV-19 (COVID-19) Vaccine against the Wild-Type and Delta Variant in Hemodialysis Patients and Healthy VolunteersImmune response after ChAdOx1 nCoV-19 Vaccine in hemodialysis patients compared to healthy volunteers.Immune response, ChAdOx1 nCoV-19 Vaccine, Hemodialysis patients, wild-type, delta variant, antibody, T-cell responseTCTR20211026002Kao Tun Roke Foundation130
招募中
不适用
Comparison of the Immunogenicity of ChAdOx1 nCoV-19 (COVID-19) Vaccine against the Wild-Type and Delta Variant in Kidney Transplant Recipients and Healthy VolunteersImmune response after ChAdOx1 nCoV-19 Vaccine in kidney transplant patients compared to healthy volunteers.Immune response, ChAdOx1 nCoV-19 Vaccine, kidney transplant patients, Wuhan Strain, B.1.617.2 (Delta) Variant, antibody, T-cell responseTCTR20211025004Kao Tun Roke Foundation200
Unknown
不适用
Safety, Efficacy of Chadox1 Ncov-19 Vaccine: Rapid Systematic Review and Meta AnalysisChAdOx1 nCoV-19 VaccineNCT05060861Assiut University2,000
招募中
不适用
To determine the safety and antibody performance in Indian adults after taking COVID-19 vaccine.CTRI/2021/03/031998Advanced Cancer for Treatment Research and Education in cancer and Tata Memorial Centre
招募中
2 期
Immune response of booster dose with ChAdOx-1 in adult who had received 2 doses of CoronaVac (COVID-19)Prevention of COVID-19 with booster-dose strategy among healthy adult who received 2-dose of Coronavac using ChAdOx1 nCoV-19 vaccine.COVID-19 Vaccine, AstraZeneca Booster , Fractional low dose vaccineTCTR20210722003Health and Aging Platform, Chulalongkorn University400